Drugs & Treatments - malecare.org

Dr. Philip Kantoff Supports the Need For Personalized Medicine for Men with Advanced Prostate Cancer

At the 2012 Genitourinary Cancers Symposium ASCO conference, Dr. Philip Kantoff (Dana-Farber Cancer Institute, Harvard Medical School Boston, MA) suggested taking a personalized approach to the individualized treatment plan for all men suffering from advanced prostate cancer. Dr. Kantoff said, “Few patients with advanced prostate cancer are currently cured with ADT (but anecdotally, long-term survival [...]

By Malecare|2017-10-19T10:51:30-04:00February 8th, 2012|Advanced Prostate Cancer, ASCO, Drugs & Treatments, General Information, Uncategorized|0 Comments

Will the FDA Approve Xgeva – It is “Up In The Air”

Prior to the formal review, the FDA has raised questions about the ultimate approval of Amgen’s Xgeva (denosumab) for men with metastatic, advanced prostate cancer who have not yet developed metastasized to the bone. Xgeva has been shown to delay tumors spreading to bones, but it does not extend life, the holy grail of the [...]

By Malecare|2017-10-19T10:51:31-04:00February 7th, 2012|Advanced Prostate Cancer, denosumab - Prolia, denosumab - Xgeva, Drugs & Treatments, General Information, Metastases, Pain, Prolia (denosumab), Uncategorized, Understanding APC|1 Comment

Video Interview Explaining That Provenge Actually Has A 7.8 Month Life Extension Advantage

As a follow up to my last post about the three posters that appeared at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium meeting I am going to share with you a video interview with Dr. Chadi Nabhan. Dr. Nabhan talks about his presentation about the phase III results of the Provenge IMPACT [...]

By Malecare|2021-02-17T11:03:37-05:00February 6th, 2012|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Provenge, Uncategorized, Understanding APC, vaccines|0 Comments

Dendreon Has Three Posters At ASCO That Add New And Great News For Men With Advanced Prostate Cancer

The American Society of Clinical Oncologists (ASCO) posted on Wednesday the abstracts from the Genitourinary Conference which is scheduled for February 2-4 in San Francisco, California. Dendreon, the creator of the immunotherapy Provenge for men with metastatic castrate resistant advanced prostate cancer has three very interesting and informative posters which will appear at the conference. [...]

By Malecare|2021-02-17T11:03:31-05:00February 3rd, 2012|Advanced Prostate Cancer, ASCO, Clinical Trials, Clinical Trials, Drugs & Treatments, Provenge, Research, Uncategorized, vaccines|0 Comments

Announcing A Compassionate Use Trial of Alpharadin

Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]

By Malecare|2020-02-04T10:11:16-05:00February 2nd, 2012|Advanced Prostate Cancer, Alpharadin (radium-223), Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Uncategorized|0 Comments